Sacubitril-Valsartan Dosing in CKD Stage 5
In adults with end-stage renal disease (CKD stage 5), start sacubitril-valsartan at 24/26 mg twice daily—half the usual starting dose—then titrate upward every 2-4 weeks to the target dose of 97/103 mg twice daily as tolerated.
Dosing Algorithm for CKD Stage 5
The FDA-approved dosing strategy for severe renal impairment (eGFR <30 mL/min/1.73 m²) is straightforward 1:
Initial Dosing
- Starting dose: 24/26 mg (sacubitril/valsartan) orally twice daily
- This represents half the standard starting dose of 49/51 mg twice daily used in patients with normal renal function
Titration Schedule
- After 2-4 weeks: Double the dose to 49/51 mg twice daily if tolerated
- After another 2-4 weeks: Increase to target maintenance dose of 97/103 mg twice daily if tolerated
- Monitor blood pressure, potassium, and renal function at each titration step
Key Monitoring Parameters
- Blood pressure: Watch for symptomatic hypotension, particularly during dialysis sessions
- Serum potassium: Risk of hyperkalemia exists but appears manageable in real-world data
- Clinical tolerance: Hypotension and hyperkalemia are the primary dose-limiting factors
Evidence Supporting Use in ESRD
While the FDA label provides clear dosing guidance 1, real-world evidence demonstrates that many dialysis patients require dose adjustments:
Effectiveness in dialysis patients: Meta-analysis of 1,597 ESRD patients on dialysis showed sacubitril-valsartan significantly reduced systolic BP by 11.09 mmHg and diastolic BP by 4.37 mmHg, improved LVEF by 7.04%, and reduced cardiovascular hospitalization risk (RR 0.63) 2. Long-term data in HFrEF patients with ESRD demonstrated lower 5-year mortality (39.3% vs 54.7%) with at least 9 months of treatment 3.
Dose reduction is common: In real-world practice, dose reduction occurred in 41% of maintenance hemodialysis patients, often due to hypotension or when combined antihypertensive medications could be discontinued 4. This suggests the target dose may not be achievable or necessary in all patients, but the FDA-recommended starting dose and titration approach remains the standard.
Critical Safety Considerations
Hypotension risk: Intradialytic hypotension is a key concern. Predictors include diabetes, higher baseline NT-proBNP, and higher interdialytic weight gain 4. Patients requiring combination antihypertensive therapy alongside sacubitril-valsartan had higher blood pressures, suggesting those on monotherapy may be at greater hypotension risk during titration.
Hyperkalemia: Despite theoretical concerns, the incidence of severe hyperkalemia was comparable to conventional treatment in pooled analyses 2. However, close monitoring remains essential, particularly in anuric dialysis patients.
Contraindications: Maintain 36-hour washout period when switching from ACE inhibitors 1. Do not use with concomitant ACE inhibitors or aliskiren in diabetic patients.
Practical Implementation
Start at 24/26 mg twice daily in all CKD stage 5 patients, regardless of dialysis status. Attempt titration to target dose (97/103 mg twice daily) over 4-8 weeks, but recognize that many patients will require lower maintenance doses due to hypotension. The goal is the highest tolerated dose, not necessarily the target dose. Monitor closely during dialysis sessions for intradialytic hypotension, and consider reducing or discontinuing other antihypertensive agents as blood pressure control improves 4.
The evidence supports using sacubitril-valsartan in ESRD patients with heart failure, with meaningful improvements in cardiac function and outcomes, despite the need for individualized dose optimization below guideline targets in many cases 2, 3, 5.